IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.080
NA - Nord America 4.702
SA - Sud America 1.647
EU - Europa 786
AF - Africa 159
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 14.392
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 4.773
US - Stati Uniti d'America 4.514
BR - Brasile 1.354
CN - Cina 784
VN - Vietnam 765
HK - Hong Kong 217
IT - Italia 180
AR - Argentina 119
GB - Regno Unito 106
IN - India 88
BD - Bangladesh 84
DE - Germania 84
CA - Canada 80
FR - Francia 78
MX - Messico 76
ZA - Sudafrica 63
IQ - Iraq 57
EC - Ecuador 51
PL - Polonia 42
RU - Federazione Russa 39
ID - Indonesia 38
ES - Italia 35
JP - Giappone 33
NL - Olanda 33
TR - Turchia 31
PK - Pakistan 27
UA - Ucraina 26
FI - Finlandia 25
CO - Colombia 23
SE - Svezia 22
VE - Venezuela 22
MA - Marocco 20
PY - Paraguay 20
UY - Uruguay 19
CL - Cile 18
UZ - Uzbekistan 18
EG - Egitto 17
CZ - Repubblica Ceca 16
PH - Filippine 16
DZ - Algeria 15
KE - Kenya 15
LT - Lituania 15
AE - Emirati Arabi Uniti 14
SA - Arabia Saudita 14
IE - Irlanda 12
JO - Giordania 12
TN - Tunisia 12
AU - Australia 11
MY - Malesia 11
NP - Nepal 11
AT - Austria 10
BO - Bolivia 10
KZ - Kazakistan 10
AL - Albania 9
JM - Giamaica 9
PE - Perù 9
PS - Palestinian Territory 9
CH - Svizzera 8
OM - Oman 8
IL - Israele 7
KR - Corea 7
DO - Repubblica Dominicana 6
AZ - Azerbaigian 5
CR - Costa Rica 5
GR - Grecia 5
LB - Libano 5
RO - Romania 5
TH - Thailandia 5
TT - Trinidad e Tobago 5
BE - Belgio 4
KG - Kirghizistan 4
NG - Nigeria 4
PT - Portogallo 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
CI - Costa d'Avorio 3
ET - Etiopia 3
HR - Croazia 3
IR - Iran 3
KW - Kuwait 3
LK - Sri Lanka 3
MD - Moldavia 3
RS - Serbia 3
SI - Slovenia 3
TW - Taiwan 3
BG - Bulgaria 2
BY - Bielorussia 2
CY - Cipro 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
HN - Honduras 2
HU - Ungheria 2
KH - Cambogia 2
LV - Lettonia 2
MM - Myanmar 2
NZ - Nuova Zelanda 2
QA - Qatar 2
SN - Senegal 2
Totale 14.374
Salva come PNG Salva come JPEG
Città #
Singapore 1.881
Ashburn 931
The Dalles 848
San Jose 828
Dallas 446
Shanghai 335
Ho Chi Minh City 277
Beijing 230
Hong Kong 205
Hanoi 165
São Paulo 121
Boardman 109
Santa Clara 98
Los Angeles 78
New York 57
Rio de Janeiro 46
Seattle 40
Da Nang 37
Belo Horizonte 35
Johannesburg 34
Warsaw 34
Orem 33
Mexico City 31
Tokyo 30
Chandler 29
Brasília 27
Haiphong 27
London 25
Dhaka 24
Helsinki 23
Milan 23
Chicago 22
Phoenix 22
Council Bluffs 21
Curitiba 21
Montreal 21
Toronto 21
Guayaquil 20
Hải Dương 20
Brooklyn 19
Campinas 18
Ribeirão Preto 18
Baghdad 17
Boston 17
Amsterdam 16
Atlanta 16
Buffalo 16
Montevideo 16
Porto Alegre 16
Stockholm 16
Rome 15
Tashkent 15
Ankara 14
Assago 14
Cape Town 14
Goiânia 14
Manchester 14
Quito 14
Frankfurt am Main 13
Paris 13
San Francisco 13
Wilmington 13
Asunción 12
Charlotte 12
Chennai 12
Hillsboro 12
Munich 12
Sorocaba 12
Amman 11
Biên Hòa 11
Buenos Aires 11
Caxias do Sul 11
Dublin 11
New Delhi 11
Reston 11
Thái Nguyên 11
Bắc Ninh 10
Cairo 10
Lauterbourg 10
Recife 10
Salvador 10
Aracaju 9
Campo Grande 9
Denver 9
Indaiatuba 9
Joinville 9
Nairobi 9
Poplar 9
Santo André 9
Santos 9
Bauru 8
Brno 8
Can Tho 8
Erbil 8
Kingston 8
Mumbai 8
Naples 8
Ninh Bình 8
Piracicaba 8
Quận Một 8
Totale 7.997
Salva come PNG Salva come JPEG
Nome #
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 183
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 168
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 142
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 116
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 89
Pembrolizumab for locally advanced cervical cancer - Authors' reply 88
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 80
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 77
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 76
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 73
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 72
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 71
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 68
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 68
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 68
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 67
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 67
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 63
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 62
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 60
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 60
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 59
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 58
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 56
A critical assessment on the role of sentinel node mapping in endometrial cancer 56
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 55
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 55
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 55
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 54
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 54
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 54
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 53
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 53
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 53
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 52
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 51
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 51
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 51
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 51
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 51
Advances in laparoscopic surgery for cervical cancer 50
"Tumori della vulva e della vagina" 50
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 50
Trabectedin as a chemotherapy option for patients with BRCA deficiency 50
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis 49
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach 49
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 49
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 49
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 48
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 48
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 48
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib 48
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 48
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial 48
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 48
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 48
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 48
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 48
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 48
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study 47
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 47
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 47
Peritoneal cytology as prognostic factor in cervical cancer 47
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 47
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 47
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 47
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 46
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 46
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 46
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 46
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 46
Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses 46
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 46
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 45
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer 45
Uterine serous carcinoma 45
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 44
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 44
Do you agree with populations that have been defined as 'noncandidates' to receiving platinum? 43
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 43
Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts 43
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features 43
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial 43
Nomogram-based prediction of cervical dysplasia persistence/recurrence 43
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 43
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 43
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 43
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance 42
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 42
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 42
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 42
Efficacy of adjuvant chemotherapy in early stage uterine leiomyosarcoma: A systematic review and meta-analysis 41
Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? 41
Fertility sparing surgery in early stage epithelial ovarian cancer 41
Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study 41
A multicentre phase 2 study of carboplatin (C) plus pegylated liposomal doxorubicin (PLO) as first-line chemotherapy for patients (pts) with advanced or recurrent endometrial carcinoma (AEC): The END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer) Group 41
Quality of life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 41
Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 41
Class II versus Class III radical hysterectomy in early cervical cancer: an observational study in a tertiary center 41
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 41
Totale 5.562
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.350
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.350
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 3 0 3
2021/202219 2 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/20269.488 1.630 779 648 982 378 614 2.940 520 566 431 0 0
Totale 14.790